CHI3L1 and Cognitive impairment: We analyzed peripheral blood CHI3L1 mRNA expression in a well-characterized cohort comprising individuals with biomarker-confirmed AD (n = 34), mild cognitive impairment (MCI; n = 31), and cognitively healthy controls (HC; n = 21).